Sorafenib dose escalation in the treatment of advanced hepatocellular carcinoma

Oncology

Volumn 82, Issue 2, 2012, Pages 119-125

  Kim, Jeong Eun ^a   Ryoo, Baek Yeol ^a   Ryu, Min Hee ^a   Chang, Heung Moon ^a   Suh, Dong Jin ^a   Lee, Han Chu ^a   Lim, Young Suk ^a   Kim, Kang Mo ^a   Kang, Yoon Koo ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Dose escalation; Hepatocellular carcinoma; Liver cirrhosis; Sorafenib; Transplantation

Indexed keywords

SORAFENIB;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ARTICLE; CANCER CONTROL; CANCER SURVIVAL; CYTOPENIA; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RASH; RISK ASSESSMENT; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PYRIDINES;

EID: 84862776834     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000336082     Document Type: Article

References (11)

1. Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917. (Pubitemid 37518510)
2. Cheng A-L, Kang Y-K, Chen Z, Tsao C-J, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang T-S, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F, de Oliveira AC, Santoro A, Raoul J-L, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz J-F, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, SHARP Investigators Study Group: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
4. Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, Faghih M, Brendel E, Voliotis D, Haase CG, Schwartz B, Awada A, Voigtmann R, Scheulen ME, Seeber S: Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23: 965-972. (Pubitemid 46202316)
5. Worns MAMD, Weinmann AMD, Pfingst K, Schulte-Sasse CMD, Messow C-M, Schulze-Bergkamen HMDP, Teufel AMDP, Schuchmann MMDP, Kanzler SMDP, Duber CMDP, Otto GMDP, Galle PRMDP: Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol 2009; 43: 489-495.
6. Majno P, Giostra E, Mentha G: Is there a customised immunosuppressive regimen for patients transplanted with hepatocellular carcinoma? J Hepatol 2005 43 577-584. (Pubitemid 41253223)
7. Yoon DH, Ryoo B-Y, Ryu M-H, Lee S-G, Hwang S, Suh DJ, Lee HC, Kim TW, Ahn C-S, Kim K-H, Moon D-B, Kang Y-K: Sorafenib for recurrent hepatocellular carcinoma after liver transplantation. Jpn J Clin Oncol 2010; 40: 768-773.
8. Bruix J, Sherman M: Management of hepatocellular carcinoma: an update. Hepatology 2010; 42: 1208-1236.
9. Duffaud F, Therasse P: New guidelines to evaluate the response to treatment in solid tumors (in French). Bull Cancer 2000; 87: 881-886. (Pubitemid 32094649)
10. Marrero JA, Lencioni R, Kudo M, Ye S, Nakajima K, Cihon F, Venook AP: Global investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafenib (GIDEON) second interim analysis in more than 1,500 patients: clinical findings in patients with liver dysfunction. ASCO Meet Abst 2011; 29: 4001.
11. Abou-Alfa GK, Amadori D, Santoro A, Figer A, De Greve J, Lathia C, Voliotis D, Anderson S, Moscovici M, Ricci S: Safety and efficacy of sorafenib in patients with hepatocellular carcinoma (HCC) and Child-Pugh A versus B cirrhosis. Gastrointest Cancer Res 2011; 4: 40-44.